New treatments on the horizon for familial hypercholesterolemia

Area of Science:

• Genetics and Cardiovascular Medicine

Background:

• Familial hypercholesterolemia (FH) is an inherited disorder characterized by high baseline LDL cholesterol (LDLc).
• Mutations in the LDLR gene impair LDL receptor function, leading to reduced hepatic uptake of cholesterol particles and elevated serum LDLc.
• FH significantly increases the risk of premature cardiovascular disease.

Purpose of the Study:

• To review the challenges in managing FH patients, particularly those with suboptimal response to conventional therapies.
• To highlight the unmet need for novel therapeutic strategies in FH management.
• To discuss emerging cholesterol-lowering medications for FH.

Main Methods:

• Review of existing literature on FH genetics, pathophysiology, and current treatment guidelines.
• Analysis of treatment outcomes with statins and combination therapies.
• Exploration of ongoing clinical development of new cholesterol-modulating drugs.

Main Results:

• Conventional therapies like statins are often insufficient for FH patients to reach target LDLc levels, with less than 30% achieving goals even with combination therapy.
• Severe FH cases may require apheresis, but less invasive options are sought.
• New drug classes targeting LDLc reduction or plaque stabilization are in development.

Conclusions:

• FH poses a significant cardiovascular risk due to high LDLc levels.
• Current therapies are inadequate for a substantial proportion of FH patients.
• Emerging pharmacological interventions hold promise as alternative or adjunctive treatments for FH.